Table 3.
Characteristics of patients with non-metastatic LAPA at restaging, according to the delivered treatment, CRT, or continued chemotherapy (n = 187)
| CRT (n = 126) |
Chemotherapy (n = 61) | P-value | |
|---|---|---|---|
| Mean age + SD | 66.1 ± 9.85 | 71.4 + 9.97 | < 0.01 |
| Performance statusa(%) ≥ 2 | 7 (5.6) | 8 (13) | 0.089 |
| Mean BMI + SD | 23.1 ± 3.77 | 23.2 ± 4.78 | 0.89 |
| Weight loss > 5% body weighta(%) | 92 (73) | 42 (69) | 0.55 |
| Diabetes (%) | 19 (15) | 8 (13) | 0.72 |
| Back paina(%) | 88 (70%) | 38 (62%) | 0.3 |
| Serum CA 19–9 levela(IU) (range) | 2180 ± 5718 | 1886 ± 4785 | 0.74 |
| Tumour location (%) | |||
| Head | 82 (65) | 43 (70) | 0.46 |
| Body | 36 (29) | 16 (26) | 0.66 |
| Tail | 8 (6.3) | 2 (3.3) | 0.5 |
| Arterial invasiona(%) | 63 (50) | 21 (34) | 0.045 |
| Continued regimen (%) | |||
| FOLFIRINOX | 29 | ||
| Gemcitabine | 32 | ||
| 5 FU | 126 | ||
| Mean number of cycles after restaging (range) | |||
| Toxicity | |||
| Grade ≥ 3 | 7 (5.5) | 15 (25) | < 0.01 |
| Neutropenia | 10 (8) | 20 (33) | < 0.01 |
| Diarrhoea | 6 (5) | 4 (7) | Ns |
| Polyneuropathy | 0 | 10 (16) | < 0.01 |
LAPA locally advanced pancreatic adenocarcinoma, BMI body mass index
aat diagnosis